Current blood-based tumor markers show limited accuracy; for instance, the loss of BAP-1 used to distinguish MM from lung cancer which exhibits highly variable sensitivity (55–85%) despite high specificity (98–100%) (Fels Elliott & Jones, 2020). This evidence concerns the gene BAP1 and Miyoshi myopathy.